Mustang Bio (Mustang Bio) Long-Term Capital Lease Obligation : $1.98 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Mustang Bio Long-Term Capital Lease Obligation?

Mustang Bio's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.98 Mil.

Mustang Bio's quarterly Long-Term Capital Lease Obligation declined from Jun. 2023 ($2.24 Mil) to Sep. 2023 ($2.12 Mil) and declined from Sep. 2023 ($2.12 Mil) to Dec. 2023 ($1.98 Mil).

Mustang Bio's annual Long-Term Capital Lease Obligation increased from Dec. 2021 ($1.69 Mil) to Dec. 2022 ($3.33 Mil) but then declined from Dec. 2022 ($3.33 Mil) to Dec. 2023 ($1.98 Mil).

Mustang Bio Long-Term Capital Lease Obligation Historical Data

The historical data trend for Mustang Bio's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mustang Bio Long-Term Capital Lease Obligation Chart

Mustang Bio Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

1.84

1.95

1.69

3.33

1.98

Mustang Bio Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															3.33	3.28	2.24	2.12	1.98

Mustang Bio (NAS:MBIO) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Mustang Bio Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Mustang Bio's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Mustang Bio (Mustang Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mustang Bio Inc (NAS:MBIO) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

377 Plantation Street, Worcester, MA, USA, 01605

Website

https://www.mustangbio.com

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies and CAR T therapies for solid tumors.

Executives

Fortress Biotech, Inc.	10 percent owner	1111 KANE CONCOURSE, SUITE 301, BAY HARBOR ISLANDS FL 33154
Rosenwald Lindsay A Md	director	375 PARK AVE, NEW YORK NY 10152
Manuel Md Litchman	director, officer: President and CEO	2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NY 10017
Eliot M Lurier	officer: Interim CFO	C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Brian Achenbach	officer: SVP, Fin. & Corp. Controller	2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NY 10014
Neil Herskowitz	director	2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Adam J. Chill	director	24 NEW ENGLAND EXECUTIVE PARK, SUITE 105, BURLINGTON MA 01803
Michael S Weiss	director	750 LEXINGTON AVE, NEW YORK NY 10022
Michael J Zelefsky	director
David J Horin	officer: Interim CFO	1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020